Deutsche Bank has initiated coverage on Germany-based medical-technology leader Ottobock (ETR: OBCK) with a Buy rating and issued a bullish long‐term growth forecast. According to the report, Ottobock is expected to deliver a core revenue compound annual growth rate (CAGR) of approximately 10% from fiscal years 2024 through 2029, alongside a projected 15% CAGR in adjusted EBITDA over the same period.
Ottobock is widely recognised as the global market leader in prosthetic limbs and orthotic solutions, with an integrated business model that spans product manufacturing and a network of patient-care clinics. Deutsche Bank’s coverage notes that approximately 55% of Ottobock’s business comes from prosthetic and orthotic mobility solutions, while the remaining 45% is generated through its international clinic network—giving it both hardware and service exposure.
Deutsche Bank highlights several factors underpinning Ottobock’s strong targeted growth:
Innovation in next-generation prosthetics and neuro-orthotics: With rising demand for microprocessor-controlled knees, AI-enabled socket systems and exoskeletons, Ottobock is well positioned to benefit. (Also supported by Ottobock’s own 9-month results showing new product launches in key regions).
Clinic network growth and international expansion: The combined model of device manufacturing plus patient-care clinics means recurring service revenue and deeper customer-engagement—helping push profitability.
Favourable demographic & reimbursement tailwinds: Aging populations, increased amputation incidence (due to diabetes, trauma, war zones) and evolving reimbursement frameworks support demand.
Operational efficiency & portfolio management: Deutsche Bank points to Ottobock’s ability to scale, improve mix and achieve margin expansion—as evidenced by margin improvements in recent results.
Under Deutsche Bank’s scenario:
A 10% revenue CAGR from 2024–29 implies that if Ottobock’s core revenue base was roughly €1.6 billion in 2024, by 2029 it could approach ~€2.6 billion (assuming straight-line growth)
A 15% EBITDA CAGR could mean significant margin expansion and profit-enhancement, with leverage on innovation and service growth.
Given this outlook, Deutsche Bank sees Ottobock’s valuation (then ~23× estimated 2026 earnings) as attractive for long-term investors.
The forecast is predicated on several assumptions and carries downside risks:
Competitive pressure from new entrants in prosthetics, digital O&P solutions and low-cost manufacturing
Reimbursement and regulatory shifts (especially as neuro-prosthetic devices evolve)
Supply-chain disruptions or delays in launching next-gen products
Macro-economic factors (currency, inflation, hospital budgets) especially relevant for medical devices
For clinics, distributors and adjacent players in the orthotics & prosthetic (O&P) market:
Rapid growth at a major OEM like Ottobock signals continued investment and upgrade cycles—especially in microprocessor joints, advanced sockets, digital workflows and clinic service models.
Equipment procurement decisions should consider that OEMs expect sustained high-growth periods—so product roadmaps and replacement cycles may accelerate.
For service providers and rehab clinics, increasing device complexity and embedded services (clinic-network expansion) may drive higher margin opportunities—but also require new training and support capabilities.
Deutsche Bank’s projection for Ottobock of ~10% revenue CAGR and ~15% EBITDA growth through 2029 reflects confidence in the future of advanced prosthetic and orthotic solutions. If the company executes as envisioned, Ottobock could set a benchmark for the O&P industry’s transformation—from purely mechanical devices to integrated smart-mobility systems with embedded services. For stakeholders in the O&P ecosystem, the message is clear: this is a period of significant evolution—and opportunity.